 | • レポートコード：MRC2303G110 • 出版社/出版日：Mordor Intelligence / 2023年2月 • レポート形態：英文、PDF、111ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の市場調査書によると、世界の炭疽治療市場規模が、予測期間中、CAGR 7.8％で増加すると推測されています。本書では、炭疽治療の世界市場について広く調査・分析を行い、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、炭疽菌種類別（皮膚炭疽菌、肺炭疽菌、消化器炭疽菌、射由来炭疽菌）分析、薬剤クラス別（抗生物質、免疫グロブリン、その他）分析、流通チャネル別（病院、薬局、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などの項目について記載しています。並びに、本書に記載されている企業情報には、Almirall, LLC、Nighthawk Biosciences, Inc. (Elusys Therapeutics Inc.)、Emergent、Paratek Pharmaceuticals, Inc.、Pfizer Inc.、Bayer AG、GSK plc、Teva Pharmaceutical Industries Ltd.、Lillyなどが含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の炭疽治療市場規模：炭疽菌種類別 - 皮膚炭疽菌における市場規模 - 肺炭疽菌における市場規模 - 消化器炭疽菌における市場規模 - 注射由来炭疽菌における市場規模 ・世界の炭疽治療市場規模：薬剤クラス別 - 抗生物質の市場規模 - 免疫グロブリンの市場規模 - その他炭疽治療の市場規模 ・世界の炭疽治療市場規模：流通チャネル別 - 病院チャネルの市場規模 - 薬局チャネルの市場規模 - その他チャネルの市場規模 ・世界の炭疽治療市場規模：地域別 - 北米の炭疽治療市場規模 アメリカの炭疽治療市場規模 カナダの炭疽治療市場規模 メキシコの炭疽治療市場規模 … - ヨーロッパの炭疽治療市場規模 ドイツの炭疽治療市場規模 イギリスの炭疽治療市場規模 フランスの炭疽治療市場規模 … - アジア太平洋の炭疽治療市場規模 中国の炭疽治療市場規模 日本の炭疽治療市場規模 インドの炭疽治療市場規模 … - 南米/中東の炭疽治療市場規模 ブラジルの炭疽治療市場規模 アルゼンチンの炭疽治療市場規模 サウジアラビアの炭疽治療市場規模 ・競争状況 ・市場機会・将来動向 |
The anthrax treatment market is expected to register a CAGR of 7.8% over the forecast period.
The COVID-19 pandemic caused disruptions in the supply chains and treatment protocols for pharmaceuticals around the world, which also influenced the global antibiotics and immunoglobulins specific to the anthrax market. On a global scale, however, it appeared infrequently in developed countries compared to developing and underdeveloped nations. For instance, as per the report published by the Annals of Medicine and Surgery in September 2022, Zimbabwe and southern Kenya have seen anthrax outbreaks with significant morbidity and low mortality during the COVID-19 pandemic. Initiatives undertaken within the countries to lower the spread of diseases have positively impacted the market’s growth. For instance, telecommunications firms were employed by countries including Nigeria, Zambia, So Tomé and Principe, and Burkina Faso to promote the supply of information about preventative and control measures. Thus, there was a significant impact on the treatment of anthrax in developing regions during the pandemic that helped the market grow. As per the analysis, the reinstatement of the supply chains and healthcare facilities is another factor that is expected to contribute to the market under consideration eventually reaching its full potential in the post-pandemic phase.
Furthermore, the anthrax treatment market will show rapid growth due to the increase in research funding and the development of novel therapies for the treatment of anthrax. Along with the aforementioned considerations, the emergence of new anthrax animal cases in various regions also supports market expansion as human exposure to animal spores might result in anthrax.
The increasing number of novel developments for the innovative and effective treatment of anthrax is one of the major factors expected to boost the growth of the anthrax treatment market. There has been a surge in the development of novel therapies due to the rising threat of exposure to Bacillus anthracis among civilian populations and military forces. For instance, in December 2021, USAMRIID researchers found a way to prevent mice from contracting the lethal disease anthrax by altering an enzyme generated by the bacterium that causes it. Their conclusion could result in the development of new antibiotics for various bacterial illnesses as well as a potential therapeutic approach for multidrug-resistant anthrax strains. The growing threat of exposure has thus led to the development of new therapies for anthrax treatment, which will have a positive impact on the growth of the anthrax treatment market in the near future.
Similarly, the new cases of anthrax among animals influence the market as it spreads to humans through animal spores. For instance, according to the public notice published by the government of Sierra Leone in May 2022, new anthrax disease cases were discovered among animals in the northern district of Port Loko in the city of Sierra Leone, West Africa. This may increase the spread to humans and increase the demand for anthrax treatment, which is expected to drive the growth of the market during the study period.
However, the high cost associated with diagnostic treatment is expected to restrain the growth of the anthrax treatment market over the analysis period.
Anthrax Treatment Market Trends
Inhalation Anthrax Segment is Expected to Dominate During the Forecast Period
Inhalation anthrax is considered to be the deadliest form of anthrax. Infection usually develops within a week after exposure, but it can take up to two months. Inhalation anthrax starts primarily in the lymph nodes in the chest before spreading throughout the rest of the body, ultimately causing severe breathing problems and shock. Without treatment, inhalation of anthrax is almost always fatal.
The inhalation anthrax segment is expected to hold a major market due to the development of new products and various collaborations between the companies. For instance, as per the study report published by the MDPI journal in February 2022, they developed a recombinant human-like humanized antibody, 35PA83 6.20, that binds the protective antigen and inhibits the production of anthrax toxins in white New Zealand rabbits that have been intranasally exposed to the deadly 9602 strain. These advanced developments in the treatment of anthrax are expected to have a positive impact on the market segment’s growth.
Furthermore, the additional funding for the development of various products for the treatment of inhaled anthrax propels the growth of the segment. For instance, in September 2021, Paratek Pharmaceuticals was awarded additional funding under the BARDA contract to advance the development of NUZYRA (omadacycline) for post-exposure prophylaxis (PEP) and the treatment of pulmonary anthrax.
Hence, all the above-mentioned factors and funding are expected to bolster the segment’s growth throughout the forecast period.
North America is Anticipated to Dominate the Anthrax Treatment Market
North America is expected to dominate the global market owing to high government funding, supportive strategies, and the presence of key players in this region. Anthrax is rare in the United States, but sporadic outbreaks do occur in wild and domestic grazing animals, such as cattle or deer. Therefore, in the United States, yearly vaccination of livestock is recommended in areas where animals have had anthrax in the past. In the United States, a few people have developed anthrax while making traditional African drums from the skins of infected animals. However, all types of anthrax infections can be treated with antibiotics, including intravenous antibiotics and prescribed medications that are given to patients based on their medical histories. Anthrax Vaccine Adsorbed (AVA) or BioThrax is the anthrax vaccine indicated for active immunization for the prevention of disease caused by Bacillus anthracis in people aged 18–65 that are at a high risk of exposure. The vaccine has been licensed since 1970 and is currently manufactured by Emergent BioSolutions, Inc.
Moreover, factors such as initiatives by organizations like the CDC supporting the development of novel therapies for the treatment of anthrax drive market growth in the Americas. For instance, as per the report published by the American Chemical Society in September 2022, the team has taken a step toward the development of a therapeutic that can treat the infection in mice without antibiotics. According to the above-mentioned study, engineered Fc-fusion of a capsule-degrading enzyme is used as the new treatment option for anthrax. As a result, new advancements in the region during the anticipated forecast period will lead to market growth.
Similarly, new contracts for products from companies are expected to boost the market growth. For instance, in April 2022, Heat Biologics, Inc. (renamed NightHawk Biosciences) and Elusys Therapeutics finalized a contract with the Canadian government to deliver ANTHIM (obiltoxaximab for injection), a treatment for inhalation anthrax, for use against a potential anthrax attack.
Hence, all the above-mentioned factors are anticipated to augment the growth of anthrax treatment in the North American region.
Anthrax Treatment Market Competitor Analysis
The anthrax treatment market is fragmented due to the availability of more treatment options from various market players. There are a considerable number of companies developing therapeutics that are quite intense. Factors such as the increase in the development of new therapies and an increase in research funding will provide considerable growth opportunities for anthrax treatment manufacturers. The major players include Nighthawk Biosciences, Inc. (Elusys Therapeutics, Inc.), Almirall, LLC, Emergent, Paratek Pharmaceuticals, Inc., GSK plc, Teva Pharmaceuticals Industries Ltd., Bayer AG, Pfizer Inc., and Lilly.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increase in Research Funding
4.2.2 Development of Novel Therapies for Treatment of Anthrax
4.3 Market Restraints
4.3.1 High Cost Associated with Diagnostic Treatment
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Anthrax Type
5.1.1 Cutaneous Anthrax
5.1.2 Inhalation Anthrax
5.1.3 Gastrointestinal Anthrax
5.1.4 Injection Anthrax
5.2 By Drug Class
5.2.1 Antibiotics
5.2.2 Immunoglobulins
5.2.3 Others
5.3 By Distribution Channel
5.3.1 Hospitals
5.3.2 Pharmacies
5.3.3 Other Distribution Channels
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Almirall, LLC
6.1.2 Nighthawk Biosciences, Inc. (Elusys Therapeutics Inc.)
6.1.3 Emergent
6.1.4 Paratek Pharmaceuticals, Inc.
6.1.5 Pfizer Inc.
6.1.6 Bayer AG
6.1.7 GSK plc
6.1.8 Teva Pharmaceutical Industries Ltd.
6.1.9 Lilly
7 MARKET OPPORTUNITIES AND FUTURE TRENDS